Venus Remedies Limited (VENUSREM.BO)
INR 301.35
(2.64%)
INR 301.35
(2.64%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 284.9 Million INR | 7.23% |
| 2022 | 265.7 Million INR | -34.76% |
| 2021 | 407.24 Million INR | -34.07% |
| 2020 | 617.65 Million INR | 717.7% |
| 2019 | -99.99 Million INR | 65.01% |
| 2018 | -285.74 Million INR | 6.9% |
| 2017 | -306.91 Million INR | -79.69% |
| 2016 | -170.8 Million INR | -1105.46% |
| 2015 | 16.98 Million INR | -67.08% |
| 2014 | 51.6 Million INR | -91.97% |
| 2013 | 642.96 Million INR | 12.19% |
| 2012 | 573.09 Million INR | 21.73% |
| 2011 | 470.77 Million INR | 1.86% |
| 2010 | 462.18 Million INR | 16.83% |
| 2009 | 395.58 Million INR | -9.99% |
| 2008 | 439.51 Million INR | 22.74% |
| 2007 | 358.09 Million INR | 41.07% |
| 2006 | 253.83 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 12.2 Million INR | -88.4% |
| 2024 Q2 | 35.1 Million INR | 187.7% |
| 2023 FY | 284.9 Million INR | 7.23% |
| 2023 Q1 | 11.8 Million INR | -89.33% |
| 2023 Q3 | 68.5 Million INR | -31.09% |
| 2023 Q4 | 105.2 Million INR | 53.58% |
| 2023 Q2 | 99.4 Million INR | 742.37% |
| 2022 Q1 | 68.9 Million INR | 2854.55% |
| 2022 Q4 | 110.55 Million INR | 236.04% |
| 2022 FY | 265.7 Million INR | -34.76% |
| 2022 Q3 | 32.9 Million INR | -38.27% |
| 2022 Q2 | 53.3 Million INR | -22.64% |
| 2021 Q2 | 231.5 Million INR | 97.86% |
| 2021 Q4 | 2.33 Million INR | -95.87% |
| 2021 Q1 | 117 Million INR | -66.68% |
| 2021 FY | 407.24 Million INR | -34.07% |
| 2021 Q3 | 56.5 Million INR | -75.59% |
| 2020 Q3 | 116.55 Million INR | -10.53% |
| 2020 Q2 | 130.26 Million INR | 560.21% |
| 2020 Q4 | 351.09 Million INR | 201.24% |
| 2020 Q1 | 19.73 Million INR | 136.67% |
| 2020 FY | 617.65 Million INR | 717.7% |
| 2019 Q3 | -9.62 Million INR | -331.25% |
| 2019 Q2 | 4.16 Million INR | 110.21% |
| 2019 Q4 | -53.8 Million INR | -459.28% |
| 2019 Q1 | -40.73 Million INR | 64.47% |
| 2019 FY | -99.99 Million INR | 65.01% |
| 2018 Q1 | -57.95 Million INR | 0.0% |
| 2018 FY | -285.74 Million INR | 6.9% |
| 2018 Q4 | -114.64 Million INR | 2.26% |
| 2018 Q3 | -117.3 Million INR | -2933.33% |
| 2018 Q2 | 4.14 Million INR | 107.14% |
| 2017 FY | -306.91 Million INR | -79.69% |
| 2016 FY | -170.8 Million INR | -1105.46% |
| 2016 Q4 | 45.25 Million INR | 0.0% |
| 2015 FY | 16.98 Million INR | -67.08% |
| 2014 FY | 51.6 Million INR | -91.97% |
| 2013 Q1 | 153.12 Million INR | 26.36% |
| 2013 Q3 | 172.28 Million INR | 0.0% |
| 2013 Q4 | 174.55 Million INR | 1.32% |
| 2013 FY | 642.96 Million INR | 12.19% |
| 2012 Q1 | 140.45 Million INR | 0.0% |
| 2012 FY | 573.09 Million INR | 21.73% |
| 2012 Q2 | 150.92 Million INR | 7.45% |
| 2012 Q3 | 160.55 Million INR | 6.38% |
| 2012 Q4 | 121.17 Million INR | -24.53% |
| 2011 FY | 470.77 Million INR | 1.86% |
| 2010 FY | 462.18 Million INR | 16.83% |
| 2009 FY | 395.58 Million INR | -9.99% |
| 2008 FY | 439.51 Million INR | 22.74% |
| 2007 FY | 358.09 Million INR | 41.07% |
| 2006 FY | 253.83 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 95.374% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.102% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 93.95% |
| Granules India Limited | 4.05 Billion INR | 92.971% |
| Indoco Remedies Limited | 984.6 Million INR | 71.064% |
| Achyut Healthcare Limited | 5.73 Million INR | -4870.482% |
| Ajanta Pharma Limited | 8.16 Billion INR | 96.509% |
| Alkem Laboratories Limited | 17.95 Billion INR | 98.413% |
| Alpa Laboratories Limited | 167.76 Million INR | -69.826% |
| Brooks Laboratories Limited | -195.91 Million INR | 245.421% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 82.36% |
| Bajaj HealthCare Limited | -837.93 Million INR | 134.001% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 62.241% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.488% |
| Eris Lifesciences Limited | 3.91 Billion INR | 92.732% |
| FDC Limited | 3.05 Billion INR | 90.666% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 101.897% |
| Gufic Biosciences Limited | 861.35 Million INR | 66.923% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 93.232% |
| Ipca Laboratories Limited | 5.47 Billion INR | 94.795% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -26.834% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 244.415% |
| Lasa Supergenerics Limited | -217.3 Million INR | 231.109% |
| Laurus Labs Limited | 1.6 Billion INR | 82.254% |
| Lupin Limited | 19.14 Billion INR | 98.512% |
| Mankind Pharma Limited | 19.12 Billion INR | 98.511% |
| Medicamen Biotech Limited | 109.31 Million INR | -160.642% |
| Medico Remedies Limited | 82.9 Million INR | -243.639% |
| Megasoft Limited | -127.46 Million INR | 323.517% |
| NATCO Pharma Limited | 13.88 Billion INR | 97.948% |
| Piramal Pharma Limited | 178.2 Million INR | -59.881% |
| RPG Life Sciences Limited | 876.6 Million INR | 67.499% |
| Sigachi Industries Limited | 571.8 Million INR | 50.174% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.702% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 90.512% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -12.549% |
| Unichem Laboratories Limited | -704.74 Million INR | 140.427% |
| Wanbury Limited | 559.56 Million INR | 49.084% |
| Windlas Biotech Limited | 581.87 Million INR | 51.036% |
| ZIM Laboratories Limited | 172.46 Million INR | -65.199% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.262% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 107.358% |
| Divi's Laboratories Limited | 16 Billion INR | 98.219% |
| Hester Biosciences Limited | 188.89 Million INR | -50.833% |
| Procter & Gamble Health Limited | 2 Billion INR | 85.824% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 36.649% |
| Bal Pharma Limited | 73.92 Million INR | -285.417% |
| Strides Pharma Science Limited | -706.14 Million INR | 140.347% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 86.865% |
| Nectar Lifesciences Limited | 49.95 Million INR | -470.386% |
| Shilpa Medicare Limited | 318.74 Million INR | 10.615% |
| Aarti Drugs Limited | 1.71 Billion INR | 83.379% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 78.806% |
| Suven Life Sciences Limited | -1.05 Billion INR | 127.114% |
| Ind-Swift Limited | 142.31 Million INR | -100.198% |
| Valiant Laboratories Limited | 3.19 Million INR | -8814.518% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 94.844% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 105.021% |
| Themis Medicare Limited | 435.23 Million INR | 34.54% |
| Hikal Limited | 696.02 Million INR | 59.066% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 98.28% |
| Sequent Scientific Limited | -358.69 Million INR | 179.43% |
| Novartis India Limited | 851.9 Million INR | 66.556% |
| Wockhardt Limited | -4.63 Billion INR | 106.154% |
| Jubilant Pharmova Limited | 771 Million INR | 63.047% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -3917.315% |
| Neuland Laboratories Limited | 3 Billion INR | 90.506% |
| Morepen Laboratories Limited | 961.59 Million INR | 70.371% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -95.124% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 414.062% |